Bartkova J, Barnes D M, Millis R R, Gullick W J
Imperial Cancer Research Fund Clinical Oncology Units, Guy's Hospital, London, England.
Hum Pathol. 1990 Nov;21(11):1164-7. doi: 10.1016/0046-8177(90)90154-w.
The presence of the c-erbB-2 protein, demonstrated immunohistochemically with antibody 21N, has been studied in 72 cases of pure mammary ductal carcinoma in situ. Sixty-one percent of cases showed positive staining. The protein was always present in large-cell comedo type of ductal carcinoma in situ, and never in small-cell cribriform/micropapillary type of ductal carcinoma in situ. When nuclear size was measured, staining was associated with tumors containing cells with large nuclei measuring up to 20 mu, and was never present in lesions containing cells with small nuclei measuring 10 mu or less. In tumors of mixed histopathologic type of ductal carcinoma in situ, variable staining was seen; the cells with small nuclei never stained, while the majority of cells with large nuclei reacted positively. The possible relevance of these findings to the biologic behavior of DCIS is discussed.
采用抗体21N进行免疫组织化学检测，研究了72例纯乳腺导管原位癌中c-erbB-2蛋白的表达情况。61%的病例显示阳性染色。该蛋白始终存在于原位导管癌的大细胞粉刺型中，而在原位导管癌的小细胞筛状/微乳头型中从未出现。测量细胞核大小时，染色与含有核直径达20μm大核细胞的肿瘤相关，而在含有核直径10μm或更小的小核细胞的病变中从未出现。在原位导管癌混合组织病理学类型的肿瘤中，可见不同程度的染色；小核细胞从不染色，而大多数大核细胞呈阳性反应。讨论了这些发现与导管原位癌生物学行为的可能相关性。
